Nanocarriers: A Reliable Tool for the Delivery of Anticancer Drugs

Overview

Journal Pharmaceutics

Publisher MDPI

Date 2022 Aug 26

PMID 36015192

Authors

Hussein Sabit

Mohamed Abdel-Hakeem

Tahsin Shoala

Shaimaa Abdel-Ghany

Mokhtar Mamdouh Abdel-Latif

Jawaher Almulhim

Mohamed Mansy

Affiliations

Soon will be listed here.

Abstract

Nanomedicines have gained popularity due to their potential therapeutic applications, especially cancer treatment. Targeted nanoparticles can deliver drugs directly to cancer cells and enable prolonged drug release, reducing off-target toxicity and increasing therapeutic efficacy. However, translating nanomedicines from preclinical to clinical settings has been difficult. Rapid advancements in nanotechnology promise to enhance cancer therapies. Nanomedicine offers advanced targeting and multifunctionality. Nanoparticles (NPs) have several uses nowadays. They have been studied as drug transporters, tumor gene delivery agents, and imaging contrast agents. Nanomaterials based on organic, inorganic, lipid, or glycan substances and synthetic polymers have been used to enhance cancer therapies. This review focuses on polymeric nanoparticle delivery strategies for anticancer nanomedicines.

Citing Articles

Drug Repurposing and Nanotechnology for Topical Skin Cancer Treatment: Redirecting toward Targeted and Synergistic Antitumor Effects.

Martins M, Veiga F, Paiva-Santos A, Pires P ACS Pharmacol Transl Sci. 2025; 8(2):308-338.

PMID: 39974652 PMC: 11833728. DOI: 10.1021/acsptsci.4c00679.

Applications of polymeric nanoparticles in drug delivery for glioblastoma.

Liu S, Tan B, Wang F, Yu Y Front Pharmacol. 2025; 15():1519479.

PMID: 39834835 PMC: 11742935. DOI: 10.3389/fphar.2024.1519479.

Transforming Medicine: Cutting-Edge Applications of Nanoscale Materials in Drug Delivery.

Tenchov R, Hughes K, Ganesan M, Iyer K, Ralhan K, Lotti Diaz L ACS Nano. 2025; 19(4):4011-4038.

PMID: 39823199 PMC: 11803921. DOI: 10.1021/acsnano.4c09566.

Self-assembled lipid-based nanoparticles for chemotherapy against breast cancer.

Liu S Front Bioeng Biotechnol. 2024; 12:1482637.

PMID: 39534673 PMC: 11555772. DOI: 10.3389/fbioe.2024.1482637.

Advancing Photodynamic Therapy with Nano-Conjugated Hypocrellin: Mechanisms and Clinical Applications.

Rajan S, Chandran R, Abrahamse H Int J Nanomedicine. 2024; 19:11023-11038.

PMID: 39502636 PMC: 11537162. DOI: 10.2147/IJN.S486014.

References

An F, Zhang X . Strategies for Preparing Albumin-based Nanoparticles for Multifunctional Bioimaging and Drug Delivery. Theranostics. 2017; 7(15):3667-3689. PMC: 5667340. DOI: 10.7150/thno.19365. View

Liu Y, Kuo C, Liou J . Anaplastic lymphoma kinase inhibitors: an updated patent review (2014-2018). Expert Opin Ther Pat. 2020; 30(5):351-373. DOI: 10.1080/13543776.2020.1738389. View

Sartaj A, Qamar Z, Qizilbash F, Annu , Md S, Alhakamy N . Polymeric Nanoparticles: Exploring the Current Drug Development and Therapeutic Insight of Breast Cancer Treatment and Recommendations. Polymers (Basel). 2021; 13(24). PMC: 8703470. DOI: 10.3390/polym13244400. View

Ahmad N, Ahmad R, Alam M, Ahmad F . Enhancement of oral bioavailability of doxorubicin through surface modified biodegradable polymeric nanoparticles. Chem Cent J. 2018; 12(1):65. PMC: 5966352. DOI: 10.1186/s13065-018-0434-1. View

Yewale C, Baradia D, Vhora I, Patil S, Misra A . Epidermal growth factor receptor targeting in cancer: a review of trends and strategies. Biomaterials. 2013; 34(34):8690-707. DOI: 10.1016/j.biomaterials.2013.07.100. View

Dion-Albert L, Cadoret A, Doney E, Kaufmann F, Dudek K, Daigle B . Vascular and blood-brain barrier-related changes underlie stress responses and resilience in female mice and depression in human tissue. Nat Commun. 2022; 13(1):164. PMC: 8748803. DOI: 10.1038/s41467-021-27604-x. View

Lee H, Fonge H, Hoang B, Reilly R, Allen C . The effects of particle size and molecular targeting on the intratumoral and subcellular distribution of polymeric nanoparticles. Mol Pharm. 2010; 7(4):1195-208. DOI: 10.1021/mp100038h. View

Kwon Y, Jo H, Bae S, Seo Y, Song P, Song M . Application of Proteomics in Cancer: Recent Trends and Approaches for Biomarkers Discovery. Front Med (Lausanne). 2021; 8:747333. PMC: 8492935. DOI: 10.3389/fmed.2021.747333. View

Yavuz M, Cheng Y, Chen J, Cobley C, Zhang Q, Rycenga M . Gold nanocages covered by smart polymers for controlled release with near-infrared light. Nat Mater. 2009; 8(12):935-9. PMC: 2787748. DOI: 10.1038/nmat2564. View

10.

Saha K, Bajaj A, Duncan B, Rotello V . Beauty is skin deep: a surface monolayer perspective on nanoparticle interactions with cells and bio-macromolecules. Small. 2011; 7(14):1903-18. PMC: 3516997. DOI: 10.1002/smll.201100478. View

11.

Gao Y, Gao D, Shen J, Wang Q . A Review of Mesoporous Silica Nanoparticle Delivery Systems in Chemo-Based Combination Cancer Therapies. Front Chem. 2020; 8:598722. PMC: 7732422. DOI: 10.3389/fchem.2020.598722. View

12.

Qian W, Sun D, Zhu R, Du X, Liu H, Wang S . pH-sensitive strontium carbonate nanoparticles as new anticancer vehicles for controlled etoposide release. Int J Nanomedicine. 2012; 7:5781-92. PMC: 3506155. DOI: 10.2147/IJN.S34773. View

13.

Peer D, Karp J, Hong S, Farokhzad O, Margalit R, Langer R . Nanocarriers as an emerging platform for cancer therapy. Nat Nanotechnol. 2008; 2(12):751-60. DOI: 10.1038/nnano.2007.387. View

14.

Gyori D, Chessa T, Hawkins P, Stephens L . Class (I) Phosphoinositide 3-Kinases in the Tumor Microenvironment. Cancers (Basel). 2017; 9(3). PMC: 5366819. DOI: 10.3390/cancers9030024. View

15.

Qin S, Li A, Yi M, Yu S, Zhang M, Wu K . Recent advances on anti-angiogenesis receptor tyrosine kinase inhibitors in cancer therapy. J Hematol Oncol. 2019; 12(1):27. PMC: 6417086. DOI: 10.1186/s13045-019-0718-5. View

16.

Li J, Dirisala A, Ge Z, Wang Y, Yin W, Ke W . Therapeutic Vesicular Nanoreactors with Tumor-Specific Activation and Self-Destruction for Synergistic Tumor Ablation. Angew Chem Int Ed Engl. 2017; 56(45):14025-14030. DOI: 10.1002/anie.201706964. View

17.

Gavas S, Quazi S, Karpinski T . Nanoparticles for Cancer Therapy: Current Progress and Challenges. Nanoscale Res Lett. 2021; 16(1):173. PMC: 8645667. DOI: 10.1186/s11671-021-03628-6. View

18.

Wang Z, Tiruppathi C, Cho J, Minshall R, Malik A . Delivery of nanoparticle: complexed drugs across the vascular endothelial barrier via caveolae. IUBMB Life. 2011; 63(8):659-67. PMC: 3142311. DOI: 10.1002/iub.485. View

19.

Fang J, Nakamura H, Maeda H . The EPR effect: Unique features of tumor blood vessels for drug delivery, factors involved, and limitations and augmentation of the effect. Adv Drug Deliv Rev. 2010; 63(3):136-51. DOI: 10.1016/j.addr.2010.04.009. View

20.

Patil Y, Sadhukha T, Ma L, Panyam J . Nanoparticle-mediated simultaneous and targeted delivery of paclitaxel and tariquidar overcomes tumor drug resistance. J Control Release. 2009; 136(1):21-9. DOI: 10.1016/j.jconrel.2009.01.021. View